title: Increased expression of CD69 on T cells as an early immune marker for human cytomegalovirus reactivation in chronic lymphocytic leukemia patients.
abstract: Reactivation of human cytomegalovirus (HCMV) remains a serious problem in immunosuppressed individuals. To investigate whether a change in the immune status can be used as an earlier marker for HCMV reactivation than the traditional PCR analysis, eight chronic lymphocytic leukemia (CLL) patients at risk for reactivation due to commencement of alemtuzumab (anti-CD52) treatment were longitudinally followed. Five series of consecutive weekly blood samples were immunophenotyped by flow cytometry to cover both the innate and adaptive immune responses. Concurrently, patients were monitored by PCR for HCMV reactivation. We found a minor upregulation of the early activation marker CD69 on NK cells immediately before HCMV was detected in circulation by PCR. Interestingly, for the specific immune response, CD69 was highly upregulated on CD3(+) T cells, especially for the CD8(+) subset, in the two patients experiencing an HCMV reactivation between 6 and 20 d before HCMV viremia was measured by PCR. Moreover, a CD4(+):CD8(+) ratio lower than 0.6 may indicate a trend toward an increased risk for viral reactivation. In conclusion, an increase in CD69 expression is a promising candidate as an early predictor of HCMV reactivation.
authors: Department of Medical Microbiology and Immunology, Aarhus University, Aarhus, Denmark. ccp@immunology.au.dk
authors: Charlotte C
authors: CC
authors: Petersen
authors: Line
authors: L
authors: Nederby
authors: Anne S
authors: AS
authors: Roug
authors: Anni
authors: A
authors: Skovbo
authors: Niels A
authors: NA
authors: Peterslund
authors: Peter
authors: P
authors: Hokland
authors: Bendt
authors: B
authors: Nielsen
authors: Marianne
authors: M
authors: Hokland
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D015703:Antigens, CD / Q000032:analysis*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis*; D015415:Biomarkers; D017252:CD3 Complex / Q000032:analysis; D016516:CD4-CD8 Ratio; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016867:Immunocompromised Host; D007155:Immunologic Factors / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000737:chemistry / Q000276:immunology; D037181:Lectins, C-Type / Q000032:analysis*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications*; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000737:chemistry / Q000276:immunology*; D014775:Virus Activation / Q000276:immunology*; D000099192:CD69 Antigens
chemical_list: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D015415:Biomarkers; D017252:CD3 Complex; D007155:Immunologic Factors; D037181:Lectins, C-Type; D000099192:CD69 Antigens